Aptose Biosciences to be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash

Aptose Biosciences Inc.

• Hanmi subsidiary will acquire all outstanding Aptose shares at C$2.41 each, a 28% premium over the 30-day VWAP of C$1.88 on TSX.
• Aptose board unanimously recommends the arrangement after unanimous recommendation from a special committee of independent directors.
• Transaction requires approval by two-thirds of votes cast and minority approval excluding Hanmi affiliates; special meeting by Jan 16, 2026.
• Non-solicitation provisions with a C$300,000 expense fee payable to Hanmi if agreement terminated under certain conditions.
• Post-closing, Aptose shares will be delisted from TSX and the company will cease reporting under Canadian securities legislation.